HC Wainwright Raises Imunon (NASDAQ:IMNN) Price Target to $13.00

Imunon (NASDAQ:IMNNGet Free Report) had its target price boosted by analysts at HC Wainwright from $12.00 to $13.00 in a report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Imunon Trading Up 17.1 %

NASDAQ IMNN opened at $1.64 on Monday. Imunon has a twelve month low of $0.48 and a twelve month high of $2.00. The stock has a 50-day moving average of $0.76 and a 200 day moving average of $0.86. The stock has a market capitalization of $15.42 million, a price-to-earnings ratio of -0.75 and a beta of 2.02.

Institutional Investors Weigh In On Imunon

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Imunon in the first quarter valued at about $83,000. Renaissance Technologies LLC purchased a new position in Imunon in the 1st quarter valued at about $76,000. Finally, Geode Capital Management LLC acquired a new stake in Imunon in the 1st quarter worth about $62,000. Hedge funds and other institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

(Get Free Report)

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.

Read More

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.